Mawer Investment Management
MRNA icon

Mawer Investment Management’s Moderna MRNA Stock Holding History

Mawer Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,901,668
Closed -$127M – 106
2024
Q3 		$127M Sell
1,901,668
-1,658
-0.1% -$152K 0.58% 40
2024
Q2 		$226M Sell
1,903,326
-13,244
-0.7% -$1.68M 1.07% 24
2024
Q1 		$204M Buy
1,916,570
+120,621
+7% +$12.2M 0.95% 27
2023
Q4 		$179M Sell
1,795,949
-25,399
-1% -$2.14M 0.91% 28
2023
Q3 		$188M Sell
1,821,348
-43,344
-2% -$4.83M 1.01% 28
2023
Q2 		$227M Sell
1,864,692
-3,843
-0.2% -$513K 1.19% 26
2023
Q1 		$287M Sell
1,868,535
-29,798
-2% -$4.92M 1.57% 19
2022
Q4 		$341M Buy
1,898,333
+85,738
+5% +$14M 1.92% 15
2022
Q3 		$214M Buy
+1,812,595
New +$275M 1.3% 23

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Mawer Investment Management's MRNA Position: Q4 2024 in Review

Mawer Investment Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 1,901,668 shares — an estimated $127M sold.

Mawer Investment Management first reported a position in MRNA in Q3 2022 and held it in 9 quarters. The position peaked at $341M in Q4 2022. 746 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Mawer Investment Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Mawer Investment Management sold 1,901,668 Moderna shares in Q4 2024, an estimated $127M.
  • Mawer Investment Management first reported a position in Moderna in Q3 2022 and held it in 9 quarters.
  • Mawer Investment Management's Moderna position peaked at $341M in Q4 2022.
  • 746 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Mawer Investment Management's 13F filing for Q4 2024, filed 12 Feb 2025.